NovaBiotics
is a developer of peptide anti-infective technology... Read moreNovaBiotics
is a developer of peptide anti-infective technology... Read more
News
Apr 21, 2022
FirstWord Pharma
NovaBiotics: NovaBiotics Announces Presentation of New Data for NM002 and NP339 at ECCMID
Jan 04, 2022
Markets Insider
NovaBiotics: NovaBiotics to Present at the H.C. Wainwright BioConnect Conference
Dec 08, 2021
Markets Insider
NovaBiotics: NovaBiotics Announces First Patient Enrollment into the Cysteamine Domain of REMAP-CAP
Oct 29, 2021
Markets Insider
NovaBiotics: NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference
Oct 05, 2021
Markets Insider
NovaBiotics: NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology
Aug 24, 2021
Markets Insider
NovaBiotics: NovaBiotics Highlights Advantages of Novel Immune-Based Approach to Combatting Fungal and Bacterial Infectious Diseases at Peptide Therapeutics Forum 2021
Aug 02, 2021
Markets Insider
NovaBiotics: NovaBiotics Announces Presentation at Upcoming Peptide Therapeutics Forum 2021
Jun 21, 2021
BioSpace
NovaBiotics: NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia
Jun 01, 2021
FinanzNachrichten
NovaBiotics: NovaBiotics Announces Publication of Data Elucidating NP339's Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy
Feb 19, 2019
Scottish Business News Network
NovaBiotics: NovaBiotics awarded £1.8m Small Business Research Innovation-Innovate UK grant funding
NovaBiotics Competitors
1
2
3
4
5
6
7
8
9
10